Compare LQDA & APPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | APPF |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.6B |
| IPO Year | 2020 | 2015 |
| Metric | LQDA | APPF |
|---|---|---|
| Price | $78.03 | $154.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $41.00 | ★ $286.78 |
| AVG Volume (30 Days) | ★ 2.4M | 347.3K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | 0.52 | ★ 1.18 |
| Revenue | $158,320,000.00 | ★ $950,822,000.00 |
| Revenue This Year | $278.87 | $19.69 |
| Revenue Next Year | $57.13 | $16.70 |
| P/E Ratio | $147.92 | ★ $122.54 |
| Revenue Growth | ★ 1031.18 | 19.72 |
| 52 Week Low | $11.85 | $142.56 |
| 52 Week High | $78.25 | $325.90 |
| Indicator | LQDA | APPF |
|---|---|---|
| Relative Strength Index (RSI) | 75.44 | 47.63 |
| Support Level | $31.23 | $145.78 |
| Resistance Level | N/A | $168.43 |
| Average True Range (ATR) | 4.14 | 7.77 |
| MACD | 0.40 | -1.21 |
| Stochastic Oscillator | 91.55 | 38.11 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.